Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1931-1936

  Choy, Hak ^a,f   Safran, Howard ^b   Akerley, Wallace ^c   Graziano, Stephen L ^d   Bogart, Jeffrey A ^d   Cole, Bernard F ^e  

^a Center for Radiation Oncology   (United States)

^b MIRIAM HOSPITAL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e BROWN UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG RESPONSE; ESOPHAGITIS; FEMALE; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031848532     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Boring, C. C., Squires, T. S., and Tong, T. Cancer statistics in 1992. CA Cancer J. Clin., 43: 7-26, 1993.
2. Ihde, D. C., and Minna, J. D. Non-small cell lung cancer. Part I: biology, diagnosis, and staging. Curr. Probl. Cancer, 15: 61-104, 1991.
3. Johnson, D. H., Chang, A. Y., Ettinger, D. S., Kim, K. M., and Bonomi, P. Recent advances with chemotherapy for NSCLC: the ECOG experience. Oncology, 12 (Suppl. 2): 67-70, 1998.
4. Belani, C. P. Multimodality management of regionally advanced non-small cell lung cancer. Semin. Oncol., 20: 302-314, 1993.
5. Dillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., Carey, R. W., Frei, E. F., III, and Green, M. R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N. Engl. J. Med., 323: 940-945, 1990.
6. Le Chevalier, T., Arriagada, R., Quoix, E., Ruffie, P., Martin, M., Tarayre, M., Lacombe-Terrier, M. J., Douillard, J. Y., and Laplanche, A. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of randomized trials in 353 patients. J. Natl. Cancer Inst., 83: 417-423, 1991.
7. Crino, L., Latini, P., Meacci, M., Corgna, E., Maranzano, E., Darwish, S., Minotti, V., Santucci, A., and Tonato, M. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small cell lung cancer. Ann. Oncol., 4: 847-851, 1993.
8. Schaake-Koning, C., van den Bogaert, W., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med., 326: 524-530, 1992.
9. Sause, W., Scott, C., Taylor, S., et al. RTOG 8808 and ECOG 4588: preliminary analysis of a Phase III trial in regionally advanced unresectable non-small cell lung cancer. J. Natl. Cancer Inst., 87: 198-205, 1995.
10. Choy, H., Akerley, W., Safran, H., Clark, J., Rege, V., Papa, A., Glantz, M., Puthawala, Y., Soderberg, C., and Leone, L. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J. Clin. Oncol., 12: 2682-2686, 1994.
11. Legha, S. S., Tenny, D. M., and Krakoff, I. R. Phase I study of Taxol using a five-day, intermittent schedule. J. Clin. Oncol., 4: 762-766, 1986.
12. Grem, J., Tutsch, K., Simon, K., Alberti, D. B., Willson, J. K., Tormey, D. C., Swaminathan, S., and Trump, D. L. Phase I study of Taxol administered as a short IV infusion daily for five days. Cancer Treat. Rep., 71: 1179-1184, 1987.
13. Donehower, R., Rowinsky, E., Grochow, L., Longnecker, S. M., and Ettinger, D. S. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat. Rep., 71: 1171-1177, 1987.
14. Brown, T., Havlin, K., Weiss, G., Cagnola, J., Koeller, J., Kuhn, J., Rizzo, J., Craig, J., Phillips, J. and Von Hoff, D. Phase I trial of Taxol given by a 6-hour intravenous infusion. J. Clin. Oncol., 9: 1261-1267, 1991.
15. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 13: 1004-1014, 1995.
16. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 22: 665-667, 1979.
17. Parness, J., and Horwitz, S. B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol., 91: 479-487, 1981.
18. Manfredi, J. J., Parness, J., and Horwitz, S. B. Taxol binds to cellular microtubules. J. Cell Biol., 94: 688-696, 1982.
19. Choy, H., Rodriguez, F. F., Koester, S., Hilsenbeck, S., and Von Hoff, D. D. Investigation of Taxol as a potential radiation sensitizer. Cancer (Phila.), 71: 3774-3778, 1993.
20. Geard, C. R., Jones, J. M., and Schiff, P. B. Taxol and radiation. J. Natl. Cancer Inst., 15: 89-94, 1993.
21. Tishler, R., Schiff, P., Geard, C., and Hall, E. Taxol: a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys., 22: 613-617, 1992.
22. Liebmann, J., Cook, J. A., Fisher, J., Teague, D., and Mitchell, J. B. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst., 86: 441-446, 1994.
23. Minarik, L., and Hall, E. J. Taxol in combination with acute and low dose rate irradiation. Radiother. Oncol., 32: 124-128, 1994.
24. Geard, C. R., and Jones, R. M. Radiation and Taxol on synchronized human cervical carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys., 29: 565-569, 1994.
25. Schiff, P. B., Fant, J., and Auster, L. A. Effects of Taxol on cell growth and in vitro microtubule assembly. J. Supramol. Struct., 2 (Suppl.): 328-335, 1978.
26. Sinclair, W. K., and Morton, R. A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat. Res., 29: 450-474, 1996.
27. Perez, C. A. Non-small cell carcinoma of the lung: dose-time parameters. Cancer Treat. Symp., 2: 131-142, 1985.
28. Blanke, C., Ansari, R., et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer (NSCLC): a Hoosier Oncology Group protocol. J. Clin. Oncol., 13: 1425-1429, 1995.
29. Arriagada, R., Le Chevalier, T., Quoix, E., Ruffie, P., de Cremoux, H., Douillard, J. Y., Tarayre, M., Pignon, J. P., and Laplanche, A. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. ASTRO plenary. Int. J. Radiat. Oncol. Biol. Phys., 20: 1183-1190, 1991.
30. Jeremic, B., Shibamoto, Y., Acimovic, L., and Milisavljevic, S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J. Clin. Oncol., 14: 1065-1070, 1996.
31. Trovo, M. G., Zanelli, G. D., Minatel, E., Franchin, G., and Gobitti, C. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 24: 11-15, 1992.
32. Soresi, E., Clerici, M., Borghini, U., Zucali, R., Leoni, M., Botturi, M., Vergari, C., Luporini, G., and Scoccia, S. A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin. Oncol., 15: 20-25, 1988.
33. Wils, J. A., Utama, I., Naus, A., and Verschueren, T. A. Phase II randomized trial of radiotherapy alone versus the sequential use of chemotherapy and radiotherapy in stage III non-small cell lung cancer. Phase II trial of chemotherapy alone in stage IV non-small cell lung cancer. Eur. J. Cancer Clin. Oncol., 20: 911-914, 1984.
34. Chang, A., Kim, K., Glick, J., Anderson, T., Karp, D., and Johnson, D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst., 85: 388-393, 199.
35. Murphy, W. K., Fossella, F. V., Winn, R. J., et al. Phase II study of Taxol in patients with untreated non-small cell lung cancer. J. Natl. Cancer Inst., 85: 384-388, 1993.
36. Roach, M. Gandara, D. R., You, H. S., Swift, P. S., Steward, K., et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J. Clin. Oncol., 13: 2606-2612, 1995.
37. Reckzeh, B., Merte, H., Pfluger, K-H., Pfab, R., Wolf, M., and Havemann, K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small cell lung cancer. J. Clin. Oncol., 14: 1071-1076, 1996.
38. Glantz, M. J., Choy, H., Kearns, C. M., Cole, B. F., Mills, P., Zuhowski, E. G., Saris, S., Rhodes, C. H., Stopa, E., and Egorin, M. J. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J. Clin. Oncol., 14: 600-609, 1996.